EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH

About EPO
Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO) is one of the leading contract research organizations (CRO) providing comprehensive worldwide services for preclinical oncology research. EPO is specialized in the development of tailored basic and translational research models to support drug development, starting with target validation and compound screening and ending in integrational in vivo studies addressing pharmacology, pharmacokinetics, biomarkers and tolerability. EPO has established models for radiation and immune oncology research. EPO’s operations meet the highest industrial standards endorsed by more than one hundred customers worldwide. Its highly motivated and qualified team guarantees short response times, consistency of service, regular updates and transparency. EPO is based at the Campus Berlin-Buch, one of Germany´s leading biotech locations. As member of the Citoxlab Group, we can in addition offer a broad range of preclinical services (general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis) to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide.